The PennZone

  • Home
  • Non-profit
  • Music
  • Marketing
  • Books
  • Entertainment
  • Health
  • Automotive
  • Legal

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
  • BJJ App mmaGPT Expands Academy Program to Support Jiu-Jitsu Instructors with AI Technique Coaching
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Coinfiliate Launches Platform to Helps Shoppers Earn Cashback and Creators Earn Referral Rewards
  • Champions for Education to Honor United Way of the Greater Lehigh Valley and Induct Three Leaders
  • Holiday Gambling Spending Expected to Rise 12% in December
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • Free Senior Housing Webinar Helps Families Plan for Aging Before a Crisis Forces Difficult Decisions

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
  • Philly ECM Programming Announces Mobile Module Programming for Philadelphia Repair Shops
  • NEW Three Fully Furnished Single-Family Model Homes at Heritage at South Brunswick
  • After 35 Years, Christian Radio Host Marina Maria Publishes the Novel She Never Forgot
  • Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage
  • Boston Industrial Solutions Launches New and Improved Siliart Website for Silicone Decorators
  • TrueNorth to Participate in 2026 Adams County Giving Spree
  • Roots for Boots Announces Rations for the Ranks to Replace MilitaryShare Beginning November 10
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia
  • BetQL Brings Data Driven 5 Star Betting Insights to the Everyday Sports Bettor
  • Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
  • Hunter Is Releasing New Music For The Holidays!
  • Tixpool.com - Naija Premier Event Reseller
  • Work 365 Expands Distributor Integrations with Companial for Microsoft Partners
  • ClassicCarJobs.us Launches Automotive Career Marketplace for Specialty Shops
  • Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
  • Dutch Mill Bulbs Launches Pink Ribbon Tulip Fundraise ~ National Breast Cancer Foundation, Inc.®
  • SecureMaine 2026 is Here -- Thursday October 8th!
  • Bluestone Laundromat Makes a Difference in the Archbald Community

Popular on PennZone

  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • The Culture and Travel Report Enters a New Chapter as Travel and Hospitality Brands Take Notice
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
  • Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter

Similar on PennZone

  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us